-

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2026

  • Completed Enrollment in LOTUS, a Phase 2b Trial of Zelicapavir in Pediatric Patients with Respiratory Syncytial Virus (RSV); Topline Data Expected in 1Q 2027
  • Initiated Dosing in RESOLVE, a Phase 2b/3 Trial of Zelicapavir in Adult Patients at High-Risk of Severe RSV Outcomes; Topline Phase 2b Data Expected in 2027
  • Topline Data from Phase 1 Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor, Now Expected in 1Q 2027
  • Investigational New Drug (IND) Application Filing for EDP-903, an Oral, Once-Daily STAT6 Inhibitor, Now Expected in 2Q 2027
  • Selected MRGPRX2 Development Candidate EPS-5336 for the Treatment of Mast Cell-Driven Diseases Including Migraine; IND Filing Targeted for 4Q 2027
  • Announced the Planned Retirement of Longstanding President and Chief Executive Officer, Jay R. Luly, Ph.D. by February 2027, and the Promotion of Tara L. Kieffer, Ph.D. to Chief Operating Officer
  • Cash and Marketable Securities Totaling $194.5 Million at September 30, 2026, as well as Continuing Retained Royalties, with Cash Runway Expected to Fund Operations into Fiscal 2029

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today reported financial results for its fiscal fourth quarter and year-ended September 30, 2026.

“During fiscal 2026 we made significant progress across our virology and immunology portfolios. In RSV, we completed enrollment in LOTUS, a Phase 2b trial of zelicapavir in pediatric patients, with topline data expected in the first quarter of 2027. We also began dosing patients in RESOLVE, a Phase 2b/3 trial of zelicapavir in adults at high risk of severe disease and anticipate reporting data from the Phase 2b portion in 2027,” said Jay R. Luly, Ph.D., President and Chief Executive Officer of Enanta Pharmaceuticals. “With no approved antiviral therapies available to treat RSV, we believe zelicapavir is well-positioned to address a substantial unmet need across both high-risk adult and pediatric populations. As we move into late-stage development, we continue to strengthen our leadership in RSV treatment and remain urgently focused on delivering zelicapavir to patients in need.”

Dr. Luly continued, “In parallel, we are advancing a growing immunology portfolio focused on developing best-in-class oral medicines that have the potential to raise the standard of care across multiple immune-mediated diseases. We expect to complete dosing in the EDP-978 Phase 1 trial by year-end 2026 and now plan to report data in the first quarter of 2027. We also plan to file INDs for EDP-903, our STAT6 clinical candidate, and EPS-5336, our newly selected MRGPRX2 development candidate, in the second and fourth quarters of 2027, respectively. We remain confident in our ability to deliver compounds with best-in-disease potential and look forward to multiple catalysts in the first half of next year.”

Fiscal Fourth Quarter and Year-Ended September 30, 2026 Financial Results

Total revenue was $12.9 million for the three months ended September 30, 2026, which consisted of royalty revenue derived from worldwide net sales of AbbVie’s hepatitis C virus (HCV) regimen MAVYRET®/MAVIRET® (glecaprevir/pibrentasvir), compared to $15.1 million for the three months ended September 30, 2025. For the twelve months ended September 30, 2026, total revenue was $63.0 million compared to $65.3 million for the same period in 2025. The decrease in the quarter and year-over-year revenue is due to a decline in AbbVie’s sales of MAVYRET®/MAVIRET®.

A portion (54.5%) of Enanta’s ongoing royalty revenue from AbbVie’s net sales of MAVYRET®/MAVIRET® is paid to OMERS, one of Canada’s largest defined benefit pension plans, pursuant to a royalty sale transaction affecting royalties earned after June 2023. For financial reporting purposes, the transaction was treated as debt, with the upfront purchase payment of $200.0 million recorded as a liability. Each quarter, Enanta records 100% of the royalty earned as revenue and then amortizes the debt liability proportionally as 54.5% of the cash royalty payments are paid to OMERS through June 30, 2032, subject to a cap of 1.42 times the purchase price, after which point 100% of the cash royalty payments will be retained by Enanta. Interest expense was $3.5 million for the three months ended September 30, 2026 and $14.1 million for the twelve months ended September 30, 2026. This compares to interest expense of $2.4 million for the three months ended September 30, 2025 and $7.7 million for the twelve months ended September 30, 2025. The increase in the quarter and year-over-year interest expense was due to an increase in forecasted royalty revenue from AbbVie’s net sales of MAVYRET®/MAVIRET® during the first half of Enanta’s 2026 fiscal year.

Research and development expenses were $26.1 million for the three months ended September 30, 2026, compared to $23.8 million for the three months ended September 30, 2025. The increase in quarterly research and development expenses was due to an increase in clinical trial expenses for Enanta’s RSV programs compared to the prior year period, driven by the Company’s RESOLVE and LOTUS studies. For the twelve months ended September 30, 2026, research and development expenses were $88.5 million compared to $106.7 million for the same period in 2025. The decrease in the year-over-year research and development expenses was due to timing of clinical trial expenses for Enanta’s RSV programs, partially offset by increased costs associated with the Company’s immunology programs.

General and administrative expenses totaled $8.8 million for the three months ended September 30, 2026, compared to $9.7 million for the three months ended September 30, 2025. For the twelve months ended September 30, 2026, general and administrative expenses were $36.8 million compared to $43.9 million in 2025. The decrease in the quarter and year-over-year general and administrative expenses was due to a decrease in stock-based compensation expenses and a decrease in legal expenses related to the Company’s patent infringement lawsuit against Pfizer.

Interest and investment income, net, totaled $1.8 million for the three months ended September 30, 2026, compared to $2.1 million for the three months ended September 30, 2025. For the twelve months ended September 30, 2026, interest and investment income, net, totaled $8.2 million compared to $9.4 million in 2025. The decrease in the quarter and year-over-year interest and investment income was due to lower interest rates.

Enanta recorded an income tax benefit of less than $0.1 million for the three months ended September 30, 2026, compared to an income tax expense of less than $0.1 million for the three months ended September 30, 2025. Enanta recorded an income tax expense of less than $0.1 million for the twelve months ended September 30, 2026 and an income tax benefit of $1.7 million for the twelve months ended September 30, 2025. Enanta recorded an income tax benefit in the twelve months ended September 30, 2025 due to interest earned on a federal income tax refund received during fiscal 2025.

Net loss for the three months ended September 30, 2026, was $23.7 million, or a loss of $0.81 per diluted common share, compared to a net loss of $18.7 million, or a loss of $0.87 per diluted common share, for the corresponding period in 2025. For the twelve months ended September 30, 2026, net loss was $68.2 million, or a loss of $2.35 per diluted common share, compared to a net loss of $81.9 million, or a loss of $3.84 per diluted common share for the corresponding period in 2025.

Enanta’s cash, cash equivalents and marketable securities totaled $194.5 million at September 30, 2026. Enanta expects that its current cash, cash equivalents and marketable securities, as well as its retained portion of future royalty revenue, will be sufficient to meet the anticipated cash requirements of its existing business and development programs into fiscal 2029.

Virology

Enanta’s virology pipeline includes the leading portfolio of RSV treatments in clinical development, consisting of zelicapavir, a once-daily N-protein inhibitor, and EDP-323, a once-daily L-protein inhibitor, both of which received Fast Track designation from the U.S. Food and Drug Administration.

  • Enrollment is completed in LOTUS, a Phase 2b trial of zelicapavir in pediatric patients with RSV. LOTUS is designed to evaluate time to complete resolution of RSV signs and symptoms as measured by the RESOLVE-P clinical scoring scale, together with the safety and antiviral activity of zelicapavir. Topline data from LOTUS are expected in the first quarter of 2027.
  • Enrollment is ongoing in RESOLVE, a Phase 2b/3 trial of zelicapavir in adults at high-risk for severe RSV disease, including patients aged 75 years or older and those with chronic obstructive pulmonary disease or congestive heart failure. The trial will evaluate time to complete resolution of 13 RSV symptoms as measured by RiiQ™, while secondary endpoints include reduction in hospitalization rate, additional clinical efficacy measures, virology and safety. Topline data from the Phase 2b portion of RESOLVE are expected in 2027.

Immunology

Enanta’s immunology pipeline is focused on designing and developing highly potent and selective oral inhibitors for the treatment of inflammatory diseases by targeting key drivers of the type 2 immune response.

  • Enanta’s lead immunology candidate, EDP-978, is a potent and selective, oral once-daily KIT inhibitor in development for the treatment of chronic urticaria and potentially other mast cell-mediated diseases. A randomized, double-blind, placebo-controlled, first-in-human Phase 1 clinical trial is ongoing and the Company expects to complete dosing by year-end 2026. Enanta now expects to report topline data from the trial in the first quarter of 2027.
  • Enanta’s second immunology candidate, EDP-903, is a potent and selective, oral once-daily STAT6 inhibitor in development for the treatment of atopic dermatitis and other diseases currently treated by dupilumab. While IND-enabling activities are complete, due to a delay in drug manufacturing, the Company is now targeting an IND filing in the second quarter of 2027.
  • Enanta’s third immunology program targets MRGPRX2, a non-canonical G-Protein-Coupled-Receptor (GPCR) expressed predominantly on mast cells, as well as peripheral neurons. Inhibiting MRGPRX2 may have potential to address multiple mast-cell driven diseases, as well as migraine. The Company selected EPS-5336 as a development candidate. EPS-5336 is a potent inhibitor of MRGPRX2 signaling in vitro and in vivo, with sub-nanomolar potency (EC50 of 0.2-0.6nM) in cellular assays via the preferred noncompetitive mechanism of inhibition. EPS-5336 also prevents skin mast cell activation in humanized MRGPRX2 mouse models. Further, EPS-5336 shows potent activity across multiple MRGPRX2 agonists and inhibits MRGPRX2-induced degranulation in migraine-relevant meningeal mast cells. EPS-5336 is highly selective for MRGPRX2 versus other GPCRs. EPS-5336 also demonstrates favorable in vitro and in vivo ADME properties, supportive of once-daily dosing potential. The Company expects to file an IND in the fourth quarter of 2027.

Corporate

  • In October 2026, Enanta announced that Jay R. Luly, Ph.D., age 70, will retire as President and Chief Executive Officer, by February 1, 2027, following 23 years of leadership with the Company. The Board of Directors has initiated a comprehensive search for Dr. Luly's successor, considering both internal and external candidates. Dr. Luly is expected to continue to serve as a strategic advisor for the remainder of 2027 to support a smooth and orderly transition. The Company also announced the appointment of Tara L. Kieffer, Ph.D., to the newly created role of Chief Operating Officer. After a 16-year career of advancement at Vertex Pharmaceuticals in research, clinical development, integrated program management and business development, Dr. Kieffer joined Enanta in 2020, most recently serving as the Company’s Chief Product Strategy Officer.
  • In August 2025, Enanta filed a patent infringement action in the Unified Patent Court (UPC) of the European Union against Pfizer Inc. and certain of its subsidiaries, seeking a determination of liability for infringement of European Patent No. EP 4 051 265 (the ’265 Patent) in connection with Pfizer’s manufacture, use, and sale of Paxlovid™ (nirmatrelvir tablets; ritonavir tablets) in the 18 EU member states participating in the UPC. Pfizer counterclaimed for revocation of the ’265 Patent. A hearing on the infringement action and counterclaim for revocation was held in September 2026. In October, the UPC released its decision concluding that the ’265 Patent is invalid. The UPC also determined that the infringement action was unfounded in light of its decision on validity. In the separate opposition proceeding filed by Pfizer with the European Patent Office (EPO) against the ’265 Patent, the EPO has set a hearing date in April 2027.
  • In September, Enanta conducted a strategic assessment of its resource allocation and operating structure to ensure alignment with its current priorities and long-term objectives. As a result of this review, the Company implemented targeted workforce reductions across the organization to increase operational efficiency, focus resources on its highest-priority opportunities and extend financial flexibility. In connection with these actions, Enanta’s workforce was reduced by approximately one-third.
  • Enanta will present at the Jefferies Global Healthcare Conference in London on November 18, 2026, and at the 9th Annual Evercore Healthcare Conference on December 2, 2026.
  • Enanta plans to issue its fiscal first quarter 2027 financial results press release on February 8, 2027.

About Enanta Pharmaceuticals, Inc.

Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for viral infections and immunological diseases. In virology, Enanta’s clinical programs are focused on the development of first-in-disease and best-in-disease treatments for respiratory syncytial virus (RSV). The Company’s immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, with KIT, STAT6 and MRGPRX2 inhibition.

Glecaprevir, a protease inhibitor discovered by Enanta, is part of the only treatment approved for curing both acute and chronic hepatitis C virus (HCV) infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta’s royalties from HCV products developed under its collaboration with AbbVie contribute ongoing funding to Enanta’s operations. Please visit www.enanta.com for more information.

Forward Looking Statements

This press release contains forward-looking statements, including statements with respect to the timeline and prospects for advancement of Enanta’s clinical programs in RSV and KIT inhibition and its preclinical immunology programs, including its programs targeting STAT6 and MRGPRX2 inhibition; the expected timing of completion of dosing and reporting of topline data from Enanta’s LOTUS and RESOLVE clinical trials; the potential of zelicapavir and Enanta’s immunology product candidates to address unmet medical needs and achieve best-in-class or best-in-disease profiles; the sufficiency of Enanta’s cash, cash equivalents and marketable securities, together with its retained portion of future royalty revenue, to fund its operations into fiscal 2029; the anticipated benefits of Enanta’s September 2026 workforce reduction; and Enanta’s planned leadership transition. Statements that are not historical facts are based on management’s current expectations, estimates, forecasts and projections about Enanta’s business and the industry in which it operates and management’s beliefs and assumptions. The statements contained in this release are not guarantees of future performance and involve certain risks, uncertainties and assumptions, which are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed in such forward-looking statements. Important factors and risks that may affect actual results include: the impact of development, regulatory and marketing efforts of others with respect to vaccines and competitive treatments for RSV; the discovery and development risks of Enanta’s programs in virology and immunology; risks of delays in patient enrollment, clinical trial conduct, drug manufacturing and IND-enabling activities; Enanta’s ability to partner its RSV or other programs; Enanta’s dependence on royalty revenue from AbbVie’s sales of MAVYRET®/MAVIRET®, a portion of which is paid to OMERS; Enanta’s need for, and ability to obtain, additional funding, and the length of its cash runway; Enanta’s need to attract and retain senior management and key research and development personnel, including risks associated with its leadership transition; Enanta’s need to obtain and maintain patent protection for its product candidates and avoid potential infringement of the intellectual property rights of others; and other risk factors described or referred to in “Risk Factors” in Enanta’s Form 10-K for the fiscal year ended September 30, 2025, as updated by periodic reports subsequently filed with the Securities and Exchange Commission. Enanta cautions investors not to place undue reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this release, and Enanta undertakes no obligation to update or revise these statements, except as may be required by law.

ENANTA PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
UNAUDITED
(in thousands, except per share amounts)
 
Three Months Ended Twelve Months Ended
September 30, September 30,

 

2026

 

 

 

2025

 

 

 

2026

 

 

 

2025

 

 
Revenue

$

12,868

 

$

15,125

 

$

63,001

 

$

65,324

 

Operating expenses
Research and development

 

26,118

 

 

23,809

 

 

88,546

 

 

106,740

 

General and administrative

 

8,789

 

 

9,702

 

 

36,835

 

 

43,933

 

Total operating expenses

 

34,907

 

 

33,511

 

 

125,381

 

 

150,673

 

Loss from operations

 

(22,039

)

 

(18,386

)

 

(62,380

)

 

(85,349

)

Interest expense

 

(3,545

)

 

(2,387

)

 

(14,074

)

 

(7,681

)

Interest and investment income, net

 

1,818

 

 

2,066

 

 

8,225

 

 

9,442

 

Change in fair value of Series 1 nonconvertible preferred stock

 

21

 

 

39

 

 

21

 

 

39

 

Loss before income taxes

 

(23,745

)

 

(18,668

)

 

(68,208

)

 

(83,549

)

Income tax benefit (expense)

 

27

 

 

(32

)

 

(40

)

 

1,660

 

Net loss

$

(23,718

)

$

(18,700

)

$

(68,248

)

$

(81,889

)

Net loss per share
Basic

$

(0.81

)

$

(0.87

)

$

(2.35

)

$

(3.84

)

Diluted

$

(0.81

)

$

(0.87

)

$

(2.35

)

$

(3.84

)

Weighted average common shares outstanding
Basic

 

29,127

 

 

21,380

 

 

29,001

 

 

21,336

 

Diluted

 

29,127

 

 

21,380

 

 

29,001

 

 

21,336

 

ENANTA PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
UNAUDITED
(in thousands)
 
September 30, September 30,

 

2026

 

 

2025

Assets
Current assets
Cash and cash equivalents

$

20,272

$

32,298

Short-term marketable securities

 

174,241

 

156,566

Accounts receivable

 

5,855

 

6,882

Prepaid expenses and other current assets

 

5,626

 

8,590

Total current assets

 

205,994

 

204,336

Property and equipment, net

 

30,858

 

35,395

Operating lease, right-of-use assets

 

35,249

 

37,549

Long-term restricted cash

 

3,360

 

3,360

Other long-term assets

 

116

 

92

Total assets

$

275,577

$

280,732

Liabilities and Stockholders' Equity
Current liabilities
Accounts payable

$

2,750

$

1,948

Accrued expenses and other current liabilities

 

14,685

 

12,751

Liability related to the sale of future royalties

 

32,968

 

30,710

Operating lease liabilities

 

4,057

 

3,146

Total current liabilities

 

54,460

 

48,555

Liability related to the sale of future royalties, net of current portion

 

88,637

 

111,132

Operating lease liabilities, net of current portion

 

50,700

 

54,757

Series 1 nonconvertible preferred stock

 

1,290

 

1,311

Other long-term liabilities

 

295

 

260

Total liabilities

 

195,382

 

216,015

Total stockholders' equity

 

80,195

 

64,717

Total liabilities and stockholders' equity

$

275,577

$

280,732

 

Contacts

Media and Investors:
Jennifer Viera
617-744-3848
jviera@enanta.com

Enanta Pharmaceuticals, Inc.

NASDAQ:ENTA

Release Versions

Contacts

Media and Investors:
Jennifer Viera
617-744-3848
jviera@enanta.com

Social Media Profiles
More News From Enanta Pharmaceuticals, Inc.

Enanta Pharmaceuticals to Participate in Upcoming Investor Conferences

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and immunological diseases, today announced that members of management will participate in the following investor conferences. 2026 Jefferies Global Healthcare Conference in London: Fireside Chat on Wednesday, November 18, 2026, at 2:30 p.m. GMT / 9:30 a.m. EST 9th Annual Evercore Healthcare Conference: Fires...

Enanta Pharmaceuticals Announces Planned Retirement of Longstanding Chief Executive Officer Jay R. Luly, Ph.D. After 23 Years of Company Leadership

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, announces today that Jay R. Luly, Ph.D., age 70, will retire as President and Chief Executive Officer, by February 1, 2027 following 23 years of leadership with the Company. Dr. Luly will continue to serve as a Strategic Advisor for the remainder of 2027 to support a smooth and orderly tr...

Enanta Pharmaceuticals Announces First Patient Dosed in the RESOLVE Phase 2b/3 Study of Zelicapavir, a Potential First-in-Disease Treatment for Respiratory Syncytial Virus (RSV)

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that the first patient has been dosed in RESOLVE, its global Phase 2b/3 clinical trial of zelicapavir in adults at high risk of severe outcomes from RSV infection. Topline data from the Phase 2b portion of the study are expected in 2027. “We are excited to advance our zeli...
Back to Newsroom